GSTP1 Ile105Val and XRCC1 Arg399Gln gene polymorphisms contribute to the clinical outcome of patients with advanced non-small cell lung cancer

L, Bu; Lb, Zhang; Mao, Xiaobo; Wang, P

doi:10.4238/gmr.15027611

Cited by 8 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies showed that there was no relationship between them,[ 14 15 ] while other studies have found that the sensitivity of GG wild-type patients to chemotherapy was significantly higher than that of patients carrying at least 1 A allele,[ 16 ] and the response rate of GA or AA genotype carriers was significantly higher than that of patients with type GG. [ 17 18 ] The response rate of chemotherapy in our research was 36.2%, which was similar to that of other studies. However, in our study, the distribution of the XRCC1 G28152A genotype was not balanced.…”

Section: Discussionsupporting

confidence: 90%

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer

Dong¹,

Wang²,

Yu³

et al. 2018

Chin Med J

View full text Add to dashboard Cite

Background:Base excision repair (BER) plays an important role in the maintenance of genome integrity and anticancer drug resistance. This study aimed to explore the role of BER gene polymorphisms in response to chemotherapy for advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.Methods:During the period from November 2009 to January 2016, a total of 152 patients diagnosed with NSCLC Stage IIIB and IV in the First Hospital of Jilin University were admitted into this study. The XRCC1 G28152A, MUTYH G972C, HOGG1 C1245G, and PARP1 T2444C polymorphisms of all the patients were detected by mass spectrometry. The logistic regression was used for statictical analysis. All tests were bilateral test, and a P < 0.05 was considered statistically significant.Results:The logistic regression model showed that the response rate of chemotherapy of the PARP1 T2444C polymorphisms, CC genotype (odds ratio [OR]: 5.216, 95% confidence interval [CI]: 1.568–17.352, P = 0.007), TC genotype (OR: 2.692, 95% CI: 1.007–7.198, P = 0.048), as well as the genotype of TC together with CC (OR: 3.178, 95% CI: 1.229–8.219, P = 0.017) were significantly higher than those of TT wild type. There was no relationship between the MUTYH G972C, XRCC1 G28152A, and HOGG1 C1245G gene polymorphisms and chemosensitivity.Conclusions:The PARP1 2444 mutation allele C might be associated with the decreased sensitivity to platinum-based chemotherapy in advanced NSCLC. These findings may be helpful in designing individualized cancer treatment.

show abstract

Section: Discussionsupporting

confidence: 90%

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer

Dong¹,

Wang²,

Yu³

et al. 2018

Chin Med J

View full text Add to dashboard Cite

show abstract

“…The Newcastle-Ottawa Scale (NOS) was used to evaluated the quality of these included studies, based on a scoring system with three components: the selection of the subjects (0–4 points); the comparability of the study groups (0–2 points); the determination of the outcome of interest (treatment response) (0–3 points). The highest NOS score for each publication was 9 points, and in this meta-analysis, two studies had a NOS score of 9 [ 11 , 31 ]; 11 studies had a NOS score of 8 [ 8 – 10 , 12 , 13 , 15 , 16 , 20 , 25 , 26 , 30 ]; eight studies had a NOS score of 7 [ 2 , 7 , 14 , 19 , 21 , 24 , 28 , 29 ]; and two studies had a NOS score of 6 [ 23 , 27 ].…”

Section: Resultsmentioning

confidence: 99%

Glutathione S-Transferase Gene Polymorphisms are Associated with an Improved Treatment Response to Cisplatin-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis

et al. 2018

View full text Add to dashboard Cite

BackgroundPrevious studies have shown an association with glutathione S-transferase (GST) gene polymorphisms in patients with non-small cell lung cancer (NSCLC) and treatment response. This study aimed to undertake a literature review and meta-analysis of GST gene polymorphisms, including GSTT1, GSTM1, and GSTP1 IIe105Val, and the treatment response to cisplatin-based chemotherapy in patients with NSCLC.Material/MethodsA literature search was undertaken of the main medical publication databases for publications, up to March 2017, on the association between GSTT1, GSTM1, and GSTP1 IIe105Val polymorphisms and the clinical outcome in patients with NSCLC treated with cisplatin-based chemotherapy. A random fixed-effects model was used to calculate the pooled odds ratio (OR) and 95% confidence interval (CI) to evaluate the associations, considering multiple genetic models. A subgroup analysis according to ethnicity was performed.ResultsTwenty-three published studies were identified that showed that both the null GSTM1 and the GG genotype of GSTP1 IIe105Val were associated with improved treatment response to cisplatin-based chemotherapy (GSTT1 present/null: OR=1.328; 95% CI, 1.074–1.643) (GSTP1 GG + AG vs. AA: OR=0.596; 95% CI, 0.468–0.759). In subgroup analysis, the GSTP1 polymorphism was significantly associated with treatment response in East-Asian patients, but not in Caucasian patients.ConclusionsMeta-analysis showed that the GG genotype of GSTP1 IIe105Val and the null GSTM1 genotype were associated with an improved treatment response to cisplatin-based chemotherapy in patients with NSCLC, especially in East-Asian patients.

show abstract

“…Numerous studies have demonstrated that both environmental and genetic factors are involved in the occurrence and progression of NSCLC (10,16). Increasing evidence suggests that genetic polymorphisms are associated with the risk of NSCLC, as well as inter-individual differences in responses to and toxicity of chemotherapy (17,18).…”

Section: Discussionmentioning

confidence: 99%

“…Both the effectiveness and toxicity of chemotherapy vary between patients. Recent studies have suggested that genetic factors play an important role in inter-individual differences in response to chemotherapy, such as the XRCC1, GSTP1 and ERCC1 genes (9)(10)(11). Cheng et al (9) reported that polymorphism in the ERCC1 gene was associated with the response of late-stage patients with NSCLC to cisplatin-based chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Role of ERCC5 polymorphisms in non‑small cell lung cancer risk and responsiveness/toxicity to cisplatin‑based chemotherapy in the Chinese population

Chen

et al. 2021

Oncol Rep

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. Cisplatin-based chemotherapy currently represents the main treatment option for patients with NSCLC. The aim of the present study was to evaluate effect of single nucleotide polymorphisms (SNPs) within the excision repair cross-complementing group 5 (ERCC5) gene on susceptibility to NSCLC, as well as the responsiveness to and toxicity of cisplatin chemotherapy. A total of 506 patients with NSCLC and 510 healthy controls were recruited for the present study. All DNA samples were genotyped by the Agena MassARRAY platform. Logistic regression analysis was carried out to assess the relationship between ERCC5 polymorphisms with NSCLC susceptibility and responsiveness to chemotherapy. The rs4771436 TG-GG genotype was associated with increased NSCLC risk. When the data were stratified according to age, sex, tobacco smoking, body mass index and histological type, ERCC5 polymorphisms (rs2016073, rs4771436, rs11069498 and rs4150330) were associated with NSCLC risk. Furthermore, the A allele and GA-AA genotype of rs11069498 were related to the response to chemotherapy. ERCC5 (rs11069498 and rs4150330) polymorphisms were associated with the increased risk of toxicity. However, rs4771436 in ERCC5 gene was significantly correlated with the reduced risk of toxicity. These results suggested a potential relationship between ERCC5 polymorphisms, the risk of NSCLC and the sensitivity to cisplatin-based chemotherapy among Chinese populations.

show abstract

GSTP1 Ile105Val and XRCC1 Arg399Gln gene polymorphisms contribute to the clinical outcome of patients with advanced non-small cell lung cancer

Cited by 8 publications

References 25 publications

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer

Glutathione S-Transferase Gene Polymorphisms are Associated with an Improved Treatment Response to Cisplatin-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis

Role of ERCC5 polymorphisms in non‑small cell lung cancer risk and responsiveness/toxicity to cisplatin‑based chemotherapy in the Chinese population

Contact Info

Product

Resources

About